162 related articles for article (PubMed ID: 36215675)
1. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.
Muchtar E; Dispenzieri A; Wisniowski B; Palladini G; Milani P; Merlini G; Schönland S; Veelken K; Hegenbart U; Geyer SM; Kumar SK; Kastritis E; Dimopoulos MA; Liedtke M; Witteles R; Sanchorawala V; Szalat R; Landau H; Petrlik E; Lentzsch S; Coltoff A; Bladé J; Cibeira MT; Cohen O; Foard D; Wechalekar A; Gertz MA
J Clin Oncol; 2023 Mar; 41(7):1393-1403. PubMed ID: 36215675
[TBL] [Abstract][Full Text] [Related]
2. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
3. Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival.
Basset M; Milani P; Foli A; Nuvolone M; Benvenuti P; Nanci M; Fabris F; Bellofiore C; Merlini G; Palladini G
Blood; 2022 Nov; 140(18):1964-1971. PubMed ID: 35772003
[TBL] [Abstract][Full Text] [Related]
4. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
5. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
6. Time to Redefine Risk-Stratification and Response Criteria in Immunoglobulin Light Chain Amyloidosis?
Jain A; Ramasamy K
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e769-e776. PubMed ID: 32653456
[TBL] [Abstract][Full Text] [Related]
7. Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.
Sharpley FA; Fontana M; Martinez-Naharro A; Manwani R; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Whelan CJ; Hawkins PN; Wechalekar AD
Haematologica; 2020 May; 105(5):1405-1413. PubMed ID: 31399529
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis.
Cohen OC; Ismael A; Pawarova B; Manwani R; Ravichandran S; Law S; Foard D; Petrie A; Ward S; Douglas B; Martinez-Naharro A; Chacko L; Quarta CC; Mahmood S; Sachchithanantham S; Lachmann HJ; Hawkins PN; Gillmore JD; Fontana M; Falk RH; Whelan CJ; Wechalekar AD
Eur Heart J; 2022 Jan; 43(4):333-341. PubMed ID: 34472567
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
[TBL] [Abstract][Full Text] [Related]
10. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.
Wechalekar AD; Schonland SO; Kastritis E; Gillmore JD; Dimopoulos MA; Lane T; Foli A; Foard D; Milani P; Rannigan L; Hegenbart U; Hawkins PN; Merlini G; Palladini G
Blood; 2013 Apr; 121(17):3420-7. PubMed ID: 23479568
[TBL] [Abstract][Full Text] [Related]
11. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A
Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.
Girnius S; Seldin DC; Meier-Ewert HK; Sloan JM; Quillen K; Ruberg FL; Berk JL; Doros G; Sanchorawala V
Bone Marrow Transplant; 2014 Mar; 49(3):434-9. PubMed ID: 24317129
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes and Effectiveness of Heart Transplantation in Patients With Systemic Light-chain Cardiac Amyloidosis.
Jeong H; Hwang I; Kim JH; Cho H; Kim MS; Lee SE; Choi HI; Jung SH; Lee JW; Yun TJ; Park JJ; Kim M; Go H; Park CS; Yoon DH; Kim JJ
Transplantation; 2022 Nov; 106(11):2256-2262. PubMed ID: 35706094
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy - A Single-Center Cohort Study of 227 Patients.
Feng J; Zhang C; Shen K; Sun J; Fang Q; Zhang L; Cao X; Zhou D; Li J; Tian Z
Circ J; 2019 Mar; 83(4):775-782. PubMed ID: 30773521
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
Wong SW; Hegenbart U; Palladini G; Shah GL; Landau HJ; Warner M; Toskic D; Jaccard A; Hansen T; Bladé J; Cibeira MT; Kastritis E; Dispenzieri A; Wechalekar A; Varga C; Schönland SO; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e493-e499. PubMed ID: 30104177
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
Kastritis E; Wechalekar AD; Dimopoulos MA; Merlini G; Hawkins PN; Perfetti V; Gillmore JD; Palladini G
J Clin Oncol; 2010 Feb; 28(6):1031-7. PubMed ID: 20085941
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.
Jimenez-Zepeda VH; Duggan P; Neri P; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e79-84. PubMed ID: 27101985
[TBL] [Abstract][Full Text] [Related]
19. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
Shen KN; Fu WJ; Wu Y; Dong YJ; Huang ZX; Wei YQ; Li CR; Sun CY; Chen Y; Miao HL; Zhang YL; Cao XX; Zhou DB; Li J
Circulation; 2022 Jan; 145(1):8-17. PubMed ID: 34503349
[TBL] [Abstract][Full Text] [Related]
20. Independent Prognostic Utility of
Choi YJ; Koh Y; Lee HJ; Hwang IC; Park JB; Yoon YE; Kim HL; Kim HK; Kim YJ; Cho GY; Sohn DW; Paeng JC; Lee SP
J Nucl Med; 2022 Jul; 63(7):1064-1069. PubMed ID: 34916248
[No Abstract] [Full Text] [Related]
[Next] [New Search]
